Alamar's Dried Blood Spot Kit Makes Hospital-Grade Proteomics Work on a Fingerstick at Home
BiohackingThe friction point in longitudinal biomarker tracking has always been collection: venipuncture requires a clinic visit, a phlebotomist, and a same-day cold-chain shipment. Alamar Biosciences has removed that dependency. Their new NULISA Dried Blood Spot (DBS) Extraction Kit extends the company’s proximity ligation assay proteomics platform to fingerstick samples that ship through standard mail—no clinic, no cold chain, no scheduling bottleneck.
How the Platform Works
NULISA (Nucleic acid-linked Immuno-Sandwich Assay) is a proximity ligation method that can detect proteins at attomolar concentrations—far below what standard immunoassays reach. The DBS kit bridges from plasma proteomics to a collection format compatible with common microsampling devices: Capitainer, Telimmune, Mitra, and Tasso are all validated. A user applies a fingerstick drop to the device, lets it dry, seals it, and mails it at ambient temperature.
Detectability across Alamar’s neurology and inflammation-focused protein panels runs 85–95% target detection, comparable to what matched venous plasma delivers on the same platform. That’s the critical number: the convenience gain doesn’t come at a meaningful sensitivity trade-off for most panel markers. Some individual proteins still perform better from venous samples, but the bulk of the panel holds.
Why This Changes the Sampling Model
The constraint that matters in longevity research—and in personal biomarker tracking—isn’t the panel itself. It’s the frequency and regularity of collection. If testing requires a clinic visit, most people test annually. If it requires a fingerstick and a stamped envelope, the barrier to monthly or quarterly sampling disappears.
Alamar’s stated intent is enabling “frequent sampling at scale” for longitudinal aging studies. That framing applies equally to individuals building multi-year biomarker records. A single timepoint tells you where your protein levels are; a quarterly record over two or three years tells you how they’re moving—which is the dataset that actually informs intervention decisions. This aligns with the collection-frequency logic that makes continuous glucose monitoring and HRV tracking more valuable than their episodic equivalents.
The proximity ligation approach also sidesteps one limitation of standard dried blood spot proteomics: standard mass-spec or immunoassay DBS methods lose sensitivity on low-abundance proteins. NULISA’s attomolar detection floor is designed for exactly the markers—low-abundance inflammatory and neurological signaling proteins—that matter most for longevity panels.
The So What
For anyone running a personal biomarker protocol, Alamar’s DBS kit removes the practical obstacle that turns annual testing into a ceiling. The platform is research-grade; the collection method is now consumer-compatible. Watch for clinical lab partnerships that bring NULISA DBS panels into direct-to-consumer testing workflows—the infrastructure is there, the pricing tier and lab access model will determine whether this reaches individual subscribers or stays confined to research cohorts for now. If you’re tracking inflammatory markers, neurological protein panels, or any assay that currently requires a clinic trip, this is the friction reduction worth monitoring.
Source: Longevity.Technology
Content created with AI assistance and reviewed for accuracy.
Join the conversation
Stack Insiders is our free community for readers who want to go deeper — share resources, ask questions, and connect with others across every vertical we cover.
Join Stack Insiders →